Dyne Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Dyne Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($108.04M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($110.86M) | Jul 28, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($110.86M) | Nov 5, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($115.36M) | Nov 5, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($115.36M) | May 8, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($115.36M) | Jul 28, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($97.13M) | Nov 5, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($65.10M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($65.10M) | Jul 28, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($65.65M) | Nov 5, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($65.65M) | Jul 28, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($65.65M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($60.21M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($64.90M) | Aug 12, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($64.90M) | Nov 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($44.19M) | May 2, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($44.19M) | Nov 12, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($44.19M) | Aug 12, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($41.39M) | Oct 30, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($52.30M) | Aug 3, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($113.89M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($115.79M) | Jul 28, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($122.37M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($105.57M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($71.96M) | Jul 28, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($69.16M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($62.27M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($66.74M) | Aug 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($45.46M) | May 2, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($42.28M) | Oct 30, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($52.76M) | Aug 3, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($35.78M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($42.77M) | Nov 3, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($30.17M) | Aug 4, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($25.13M) | May 2, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($13.52M) | Nov 4, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($8.68M) | Aug 5, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($7.85M) | May 6, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($3.63M) | Nov 5, 2020 |